Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.
Response Evaluation Criteria in Cancer of the Liver
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on… Expand
2018
2018
AIM
To evaluate the potential value of texture analysis (TA) based on contrast-enhanced magnetic resonance imaging (MRI) for… Expand
Review
2017
Review
2017
Sorafenib has been the only approved systemic therapy for hepatocellular carcinoma until very recently. However, the radiologic… Expand
2016
2016
The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on… Expand
2016
2016
The goal of the study was to evaluate the efficacy and safety of balloon‐occluded transarterial chemoembolization (B‐TACE) of… Expand
2014
2014
BackgroundTo test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved… Expand
2013
2013
PURPOSE
In order to detect an early response to anti-angiogenic therapy, this study aims at analyzing specific effects of a… Expand
Highly Cited
2010
Highly Cited
2010
The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to… Expand